3 days ago
Roche extends trials of antibiotic against resistant superbug, FT reports
Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had potential to tackle a common superbug that has become resistant to other treatments, The Financial Times's Hannah Kuchler reports. If successful, it would be the first new class of antibiotic capable of killing acinetobacter or any other 'Gram-negative' bacteria to be developed for more than 50 years, the report says. Roche plans to launch a phase 3 trial for zosurabalpin at the end of the year, or early next year, Kuchler writes.
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders' Hot Stocks on TipRanks >>
Read More on RHHBY:
Disclaimer & DisclosureReport an Issue
Tandem Diabetes, Roche enter patent settlement agreement
Roche announces EMA's CHMP has adopted positive opinion for Itovebi
Genentech announces two-year follow-up data from STARGLO study
Roche's Genentech announces FDA approval of Susvimo for diabetic retinopathy
Trump Trade: White House announces 'Golden Dome' missile-defense shield
